Floatz logo

Dilanubicel

Hematopoietic and Lymphoid Cell Neoplasm

Fred Hutchinson Cancer CenterCell therapyPhase 2Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
89/ 100

Competitive context

116 Active assets in the Hematopoietic and Lymphoid Cell Neoplasm cohort.

Asset / SponsorPhaseRating
Fludarabine
National Cancer Institute (NCI)
Phase 3BB
Pegloticase
M.D. Anderson Cancer Center
Phase 4BB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 2BB
Rasburicase
M.D. Anderson Cancer Center
Phase 4BB
HYDROMORPHON
M.D. Anderson Cancer Center
Phase 4BB

View all 50 →

Same molecule, other indications

Dilanubicel is also rated in:

acute myeloid leukemia, del(5q31-q32)Dormant
CCC
Indicative ·
52 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
CCC
Indicative ·
52 / 100
View asset →
acute myeloid leukemia with 11q23 abnormalitiesDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →